Akèy › Kansè tete negatif triple › Lwizyàn
Etid klinik pou Kansè tete negatif triple nan Lwizyàn
6 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Lwizyàn.
Vil nan Lwizyàn
Tèks ofisyèl etid la (Anglè)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0109), Alexandria
- Louisiana State University Health Sciences Shreveport ( Site 0029), Shreveport
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Ochsner Clinic Foundation ( Site 0021), New Orleans
- Louisiana State University Health Sciences Shreveport ( Site 0053), Shreveport
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Mary Bird Perkins Cancer Center, Baton Rouge
- University Medical Center - New Orleans, New Orleans
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Ochsner Clinic Foundation, Covington
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06926868A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
- LSU Health Sciences Center, Shreveport
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2025 · NCT06700070CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Louisiana State University, New Orleans
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Jan 7, 2025 · NCT06230185Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.